扩大使用-葡萄糖共运输体2抑制剂:除了心力衰竭以外的证据,减少了喷射分数
Erika Michelle Schoenborn1, Preston Trudell Skersick2, Claire Maxine Thrasher2
1Department of Pharmacy, East Carolina University Health Medical Center, Greenville, North Carolina, USA.
Pharmacotherapy
|June 16, 2023
概括
-葡萄糖共传输体2抑制剂 (SGLT2i) 现在是第一线心力衰竭 (HF) 治疗. 本综述详细介绍了SGLT2i在HF类型,机制和正在进行的心血管疾病研究中的有效性.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
背景情况:
- -葡萄糖共运输体2抑制剂 (SGLT2i) 最初用于糖尿病管理.
- 达帕格利弗洛辛在心力衰竭中取得的成功,刺激了广泛的心血管研究.
- 现在,SGLT2i已成为心力衰竭的第一线指南导向医学治疗的一部分.
研究的目的:
- 审查不同心血管疾病中SGLT2抑制剂的临床试验数据.
- 专注于SGLT2i在心力衰竭中的有效性,其中包括保留喷射分数 (HFpEF) 和急性不补偿心力衰竭 (ADHF).
- 探索SGLT2i机制,成本效益,以及双重SGLT1/2封锁.
主要方法:
- 对14项临床试验的综合审查,这些试验调查了SGLT2抑制剂在心血管疾病中的作用.
- 对行动机制,成本效益和双重封锁研究的分析.
- 包括一些正在进行的试验来绘制研究格局的地图.
主要成果:
- 多种SGLT2抑制剂显示出对心血管的益处,无论左心室喷射率 (LVEF).
- 在HFrEF中确定的疗效和在HFpEF和ADHF中出现的益处.
- 目前正在进行的研究继续定义SGLT2i心血管应用的全部范围.
结论:
- SGLT2 抑制剂已成为心力衰竭管理的基石.
- 目前正在进行进一步的研究,以充分阐明SGLT2i机制并扩大其治疗作用.
- 本综述为临床医生提供了关于SGLT2i在心血管保健中的全面资源.
相关概念视频
01:30Heart Failure V: Medical Management
16
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
16
01:55Secondary Active Transport
121.8K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
121.8K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
469
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
469
01:22Heart Failure Drugs: Diuretics
426
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
426
01:22Heart Failure VI: Adjunct Therapies
17
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
17
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
240
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
240